for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Hyundai Bioscience Co Ltd

048410.KQ

Latest Trade

47,150.00KRW

Change

-1,300.00(-2.68%)

Volume

2,606,102

Today's Range

46,900.00

 - 

50,600.00

52 Week Range

9,470.00

 - 

66,300.00

As of on the KOSDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
48,450.00
Open
49,500.00
Volume
2,606,102
3M AVG Volume
138.13
Today's High
50,600.00
Today's Low
46,900.00
52 Week High
66,300.00
52 Week Low
9,470.00
Shares Out (MIL)
36.16
Market Cap (MIL)
1,704,844.00
Forward P/E
--
Dividend (Yield %)
--

Latest Developments

More

Hyundai Bioscience Develops Injection Drug For Potential Treatment Of Severe Cases Of COVID-19

Hyundai Bioscience Says Co's COVID-19 Oral Drug Solved Niclosamide's Inhibitory Concentration Problem

Hyundai IBT to change co name to Hyundai Bioscience

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Hyundai Bioscience Co Ltd

HYUNDAI BIOSCIENCE CO., LTD. it is a Korea-based company mainly engaged in the manufacturing and sale of bio cosmetics and hair tonic products. It develops functional daily necessities such as shampoos, mask packs, creams, and tumor-targeted drug. The Company also sells liquid crystal display (LCD) monitors and digital signage display products. The Company distributes its products in domestic market, as well as to the overseas markets, including Europe, America and Japan.

Industry

Personal & Household Prods.

Contact Info

106, Apogongdan-Gil, Apo-Eup

39670

South Korea

+82.54.4306425

http://www.hyundaibioscience.com/

Executive Leadership

Sang Gi Oh

Chief Executive Officer, Director

Je Man Jang

Chief Operating Officer, Vice President, Director

Yeong Gwon Jung

Assistant Managing Director

Chang Hyeon Lee

Assistant Managing Director

Jong Sik Park

Internal Auditor

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
93.29
Price To Book (MRQ)
28.81
Price To Cash Flow (TTM)
967.79
Total Debt To Equity (MRQ)
60.08
LT Debt To Equity (MRQ)
46.76
Return on Investment (TTM)
-2.96
Return on Equity (TTM)
-2.53

Latest News

Latest News

South Korea IPO boom continues as shares in vaccine firm SK Bioscience surge 30% on debut

South Korean firm SK Bioscience Co Ltd shares rocketed 30% on their first day of trading on Thursday, as investor bets on the COVID-19 vaccine developer and maker's prospects turned it into a nearly $12 billion business.

Vaccine developer SK Bioscience to raise $1.3 billion in South Korea's largest IPO since 2017

South Korean vaccine developer SK Bioscience Co Ltd is expected to raise 1.5 trillion won ($1.33 billion) in the country's largest IPO since 2017, after pricing the listing at the top of an indicative range, it said on Monday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up